Related references
Note: Only part of the references are listed.Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS
Stephane Bouchet et al.
CLINICA CHIMICA ACTA (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on 4-Anilinoquinazolines
Matthias Scheffler et al.
CLINICAL PHARMACOKINETICS (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on Pyrimidines, Pyridines and Pyrroles
Paola Di Gion et al.
CLINICAL PHARMACOKINETICS (2011)
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib
Thierry Buclin et al.
LANCET ONCOLOGY (2011)
A rapid and fully-automated method for the quantitation of tricyclic antidepressants in serum using turbulent-flow liquid chromatography-tandem mass spectrometry
Autumn R. Breaud et al.
CLINICA CHIMICA ACTA (2010)
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response
Edgar Faber et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry
R. Honeywell et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma
Benoit Blanchet et al.
CLINICA CHIMICA ACTA (2009)
Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib
Sandra Roche et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry
A. Haouala et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
N. Widmer et al.
BRITISH JOURNAL OF CANCER (2008)
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
Patrick J. Medina et al.
CLINICAL THERAPEUTICS (2008)
Validation of new methods
Frank T. Peters et al.
FORENSIC SCIENCE INTERNATIONAL (2007)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics
Helen C. Swaisland et al.
CLINICAL PHARMACOKINETICS (2006)
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry
Karine Titier et al.
THERAPEUTIC DRUG MONITORING (2005)
A parallel micro turbulent flow chromatography-tandem mass spectrometry method for the analysis of a pharmaceutical compound in plasma
C Chassaing et al.
CHROMATOGRAPHIA (2005)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
